Free Trial

Immunocore's (IMCR) Buy Rating Reaffirmed at HC Wainwright

Immunocore logo with Medical background
Remove Ads

HC Wainwright reiterated their buy rating on shares of Immunocore (NASDAQ:IMCR - Free Report) in a research report released on Wednesday morning,Benzinga reports. They currently have a $100.00 target price on the stock.

A number of other analysts have also recently issued reports on IMCR. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 price objective on shares of Immunocore in a research note on Friday, March 7th. Needham & Company LLC reiterated a "buy" rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Immunocore presently has an average rating of "Moderate Buy" and an average target price of $65.64.

Get Our Latest Stock Analysis on Immunocore

Immunocore Stock Performance

Shares of IMCR stock traded up $0.53 during trading hours on Wednesday, reaching $28.80. 345,561 shares of the company traded hands, compared to its average volume of 432,123. The firm has a 50-day moving average price of $30.08 and a 200 day moving average price of $31.31. The company has a market cap of $1.44 billion, a P/E ratio of -30.32 and a beta of 0.79. Immunocore has a 12-month low of $27.19 and a 12-month high of $66.00. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. grew its stake in shares of Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after acquiring an additional 109,206 shares in the last quarter. Assetmark Inc. grew its stake in Immunocore by 6.5% during the 3rd quarter. Assetmark Inc. now owns 30,555 shares of the company's stock worth $951,000 after purchasing an additional 1,878 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new stake in Immunocore during the 3rd quarter worth about $866,000. GSA Capital Partners LLP purchased a new position in shares of Immunocore in the 3rd quarter valued at about $406,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Immunocore by 7.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company's stock worth $13,297,000 after buying an additional 29,689 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

About Immunocore

(Get Free Report)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

Featured Stories

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Should You Invest $1,000 in Immunocore Right Now?

Before you consider Immunocore, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.

While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads